FDA Dermal Filler Approvals and Adverse Events: A 30-Year MAUDE and PMA Analysis

Introduction: The Data Behind Soft Tissue Fillers

Dermal fillers have transitioned from niche cosmetic treatments to mainstream aesthetic procedures, constituting a multi-billion dollar segment of the global medical device market. In the United States, the Food and Drug Administration (FDA) regulates dermal fillers as Class III medical devices. Because they are classified under the highest risk tier, they must go through the rigorous Premarket Approval (PMA) pathway rather than the simpler 510(k) notification process.

To understand the safety, regulatory clearance patterns, and post-market safety profiles of these products, we conducted a comprehensive quantitative analysis of the FDA's public registration registries. Our analysis covers:

1. 1,038 PMA approvals and supplements registered under the dermal filler product codes (LMH for facial dermal implants and PKY for hand dermal implants).
2. 22,247 adverse event reports filed in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database over a 30-year period.
3. 7 recall events recorded in the FDA’s medical device recall database.

This report details our findings, providing manufacturers, regulatory affairs professionals, and clinicians with a clear, data-driven view of the dermal filler product lifecycle.

Dermal Filler PMA Approvals: Market Concentration

Dermal fillers require a full PMA application to prove clinical safety and efficacy before market entry. Once a PMA is approved, any subsequent modifications to the design, manufacturing process, labeling, or indications are filed as PMA supplements.

Our registry extract shows a total of 1,038 PMA approvals and supplements under the LMH and PKY product codes. The approvals are heavily concentrated among a small group of multinational medical aesthetics companies.

Top Applicants for Dermal Filler PMAs

The following table lists the top applicants by count of approved PMAs and supplements:

Data source: FDA PMA database; analysis by MedDeviceGuide.

Key Insights on PMA Data

• The Big Three Domination: The top three applicants — Merz, Q-Med (Galderma), and Allergan (AbbVie) — account for 83.6% of all approved dermal filler PMA records.
• Supplement Frequency: The high volume of records for individual applicants is driven by lifecycle modifications (supplements) rather than new original PMAs. Dermal filler manufacturers frequently optimize formulations, expand indications (e.g., adding lip, cheek, or temple hollowing indications), modify syringe designs, or transfer manufacturing lines to new facilities.

30 Years of MAUDE Adverse Events: Safety Profiling

To assess the post-market safety profile of dermal fillers, we analyzed 22,247 adverse event reports associated with LMH and PKY product codes in the FDA's MAUDE database.

Event Type Classification

Under FDA reporting rules, adverse events must be categorized by severity and device behavior. For dermal fillers, the breakdown is as follows:

The "No event type specified" bucket captures reports in which the submitter did not assign a health-consequence classification (e.g., complaints logged before a clinical outcome could be confirmed), rather than events with no consequence at all.

Data source: FDA MAUDE database; analysis by MedDeviceGuide.

The Patient-Device Link in Aesthetics

• Operator-Dependent Complications: Unlike typical medical devices where mechanical failure (malfunction) dominates MAUDE reports, 83.2% of dermal filler adverse events are classified as Injuries. Complications such as lumps, nodules, swelling, bruising, skin necrosis, or vascular occlusion are usually clinical sequelae of the injection procedure or host tissue response, rather than structural device failures.
• Low Death Rate: The 16 reported deaths constitute 0.07% of all reports. These rare, high-severity reports typically involve off-label use in sensitive anatomical regions or complications associated with systemic hypersensitivity and infection.

Top Dermal Filler Brands in MAUDE Reports

The following list highlights the top brand names appearing in the MAUDE registry for dermal fillers:

1. SCULPTRA (PLLA) — 1,553 reports
2. JUVEDERM VOLUMA XC/LIDO (Allergan) — 979 reports
3. JUVEDERM VOLUMA XC 27G 2 X 1ML (Allergan) — 877 reports
4. JUVEDERM ULTRA XC TSK US (Allergan) — 681 reports
5. UNKNOWN VOLBELLA (Allergan) — 644 reports
6. VOLBELLA WITH LIDOCAINE (Allergan) — 639 reports
7. JUVEDERM VOLUMA WITH LIDOCAINE 1ML (Allergan) — 614 reports
8. RADIESSE DERMAL FILLER (Merz) — 597 reports
9. JUVEDERM (UNSPECIFIED) (Allergan) — 499 reports
10. JUVEDERM ULTRA PLUS XC TSK US (Allergan) — 493 reports
11. ZYPLAST COLLAGEN IMPLANT (Legacy) — 467 reports
12. VOLIFT WITH LIDOCAINE (Allergan) — 455 reports
13. RADIESSE INJECTABLE IMPLANT (Merz) — 443 reports
14. JUVEDERM VOLLURE XC 2X1 ML (Allergan) — 423 reports

Note: Juvederm-branded products across different packaging and volume configurations represent the largest aggregate block of reports, reflecting its massive market share in the United States.

Adverse Event Timeline Trends (1993–2026)

The volume of dermal filler adverse event reports in the MAUDE database has grown significantly over the last three decades, matching the rising popularity of these procedures.

Annual Report Volume Trend:
1993: 1
1996: 102
2000: 200
2005: 130
2008: 309
2009: 1,221  [First major reporting peak]
2014: 787
2015: 887
2017: 1,510
2018: 1,810  [Historical reporting peak]
2021: 1,422
2022: 1,380
2023: 1,479
2024: 1,393
2025: 1,825  [High-volume baseline]
2026: 729    [Partial year data]

Key Trend Analysis:

• The 2009 Peak: The sudden jump to 1,221 reports in 2009 aligns with increased post-market safety communications from the FDA regarding delayed-onset inflammatory nodules and hypersensitivity reactions associated with newly cleared formulations.
• The 2018 Peak & Steady State: The peak in 2018 (1,810 reports) and the high baseline through 2025 reflect both market volume expansion and improved compliance with post-market vigilance reporting requirements by major manufacturers.

Medical Device Recalls: Exceptionally Low Failure Rate

While adverse event volume in the MAUDE database is high, structural failures that lead to official recalls are exceptionally rare. Over the entire history of the registry, only 7 official recalls have been recorded for LMH and PKY products:

Data source: FDA Recalls database; analysis by MedDeviceGuide.

Root Cause Analysis

• No Active Recalls: All 7 recalls carry an FDA status of Terminated — FDA's term for a recall that has been concluded and closed (i.e., the firm completed its correction/removal efforts and FDA agreed the action could end), not a recall that was aborted. There are no open, ongoing dermal filler recalls.
• Manufacturing Quality & Distribution Control: The root causes are split between manufacturing component nonconformity (Merz), distribution/storage temperature deviations (Orthovita), and syringe design malfunctions (Enhancement Medical). This underscores the fact that dermal filler recalls are regulatory and quality-control events rather than signs of systemic product safety failures.

Conclusion & Strategic Recommendations for RA/QA

1. Vigilance Planning for "Injury" Classifications: Dermal filler manufacturers must design their post-market surveillance (PMS) and vigilance plans to handle a high volume of procedure-related "Injury" reports in MAUDE. Because complications are highly operator-dependent, training programs, clear Instructions for Use (IFU), and needle/cannula selection guides are critical risk-mitigation measures.
2. QMS Integration Under QMSR: With the FDA's Quality Management System Regulation (QMSR) in effect since February 2, 2026, manufacturers must ensure that their supplier controls and raw material inspections (especially for hyaluronic acid cross-linking reagents and polymer sourcing) are fully aligned with ISO 13485:2016.
3. Indication Expansion Strategy: Given that market leaders maintain hundreds of PMA supplements, new entrants should build a modular PMA strategy — launching with a narrow, well-defined facial indication (e.g., nasolabial folds) to secure the initial approval, and then systematically using supplements to expand into lips, cheeks, hands, and other high-volume treatment areas.